Type 2 Diabetes Clinical Trial
Glycemic variability has been associated with mortality in hospitalized patients with
hyperglycemia. However, it is unknown how modulation of glycemic variability would impact
outcomes. One possibility is that glycemic variability could impact autonomic tone. In
particular, heart rate variability (HRV) measurement is a sensitive marker for measuring
autonomic tone, and aberrations in HRV have been associated with mortality. The current
randomized pilot study will compare the effects of continuous intravenous (IV) insulin and
subcutaneous basal bolus insulin on glycemic variability and autonomic tone in hospitalized
non-critically ill patients with diabetes. Non-critically ill patients who are hyperglycemic
or are requiring at least 20 units of insulin per day will be included. Patients with
conditions that preclude accurate HRV readings (such as atrial fibrillation or paced
rhythms) will be excluded. Patients randomized to intravenous insulin will receive the
therapy for 24 hours according to our standard hospital guideline. Patients randomized to
subcutaneous (SQ) insulin will receive basal bolus therapy using insulin analogues. All
therapies will begin between 8 and 10 AM. Patients will undergo repeated heart rate
variability recordings during the 24 hour period. Blood draws will be collected at baseline
and at 24 hours for measurement of catecholamines, insulin, and c-peptide. Glycemic
variability will be measured using a continuous subcutaneous glucose monitor and reported as
coefficient of variation. The primary outcome measure is low frequency-to-high frequency
power spectrum ratio of heart rate variability.
1. Glycemic variability is associated with unfavorable changes in autonomic tone, as
assessed by low frequency (LF)/high frequency (HF) HRV ratio, independent of changes in
overall glycemia.
2. Short-term increases in glycemic variability, followed by more prolonged glycemic
stability are observed in generalized hospitalized patients treated with intravenous
insulin compared to standardized basal bolus therapy. LF/HF HRV differs among subjects
receiving intravenous compared to subcutaneous insulin.
3. Glycemic variability differs among subjects receiving intravenous compared to
subcutaneous insulin
n/a
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
| Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
| Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
| Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
| Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
| Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
| Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
| Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
| Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
| Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
| Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
| Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
| Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
| Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
| Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
| Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |